Xuesong He
- Ada Forsyth Institute, Inc. (no department on record)
From the FY2024 NIH awards this investigator leads as contact PI. The department is the award's.
FY2024 NIH rank #6,766
- R01 Holder
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 10282239Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
NIH Funding · FY2024
Linked Award Amount
$1.8M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#6,766
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2024 award records by amount
NIH award records listing Xuesong He as a PI. Multi-PI records show the full award amount for context.
- 5R01DE029479-04R01Co-investigatorPreventing dental caries through targeted treatment of acid-producing bacteria$682Kaward amount
- 2R01DE023810-12R01Contact PIDomestication and characterization of TM7-the most elusive oral phylum$587.9Kaward amount
- 5R01DE030943-03R01Contact PIHost tRNA-derived small RNAs (tsRNAs) mediate interactions between host and oral microbes$481.4Kaward amount
Award organization
Organizations that administered FY2024 awards listing Xuesong He as a PI.
FY2024 award administered by Ada Forsyth Institute, Inc. (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardAda Forsyth Institute, Inc.
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #6766
- 2025$2M Cumulative Funding
- 2025R01 Grant Holder
- 2026$5M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Xuesong He.